ClinicalTrials.gg
RecruitingNCT04028011Updated Nov 18, 2026

Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea

An observational study in Obstructive Sleep Apnea and Periodic Leg Movements, Excessive, Sleep-Related, sponsored by Acurable Ltd.. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Acurable Ltd. · Observational

How we know

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 1 month later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
296
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.

Planned enrollment
13th of 21
296 · median 338
Started
2019
with 14 others
Observational
21 of 82
5 open now
Primary completion
2028-12
later than 18 of 18 live
Registered
41st of 82
by date

Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 15 that started in 2019, is one of 21 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 41st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Sleep Apnea, Obstructive with a site in Spain, or all of them as a file.
02

Study summary

This trial will aim to test a new wearable device for the diagnosis of Sleep Apnoea.

Read the detailed description

This clinical trial will test a new wearable device for the diagnosis of Sleep Apnoea against Multi-channel polygraphy and Polysomnography.

For Group 1 and Group 2, the patients who have been referred for a sleep apnoea diagnosis will undergo in-hospital overnight polysomnography while wearing the new wearable device. Performance (i.e. sensitivity and specificity) of the new device will be assessed against the gold standard system.

For Group 3 and 4, the patients who have been referred for a sleep apnoea diagnosis will undergo in-hospital overnight polysomnography while wearing the new wearable device and a CE-marked oximeter.

For Group 5, patients presenting clinical criteria of Restless Legs Syndrome who are being evaluated via sleep studies as part of a routine clinical care will undergo an overnight polysomnography while wearing the new wearable device system.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Periodic Leg Movements, Excessive, Sleep-Related
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who have been referred for suspicion of sleep apnoea

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have been referred to a sleep clinic due to suspicion of sleep apnoea.
  • patients between the age of 18 yo and 80 yo

Exclusion criteria

Exclusion Criteria:

  • who are not fluent in Spanish, or who have special communication needs.
  • Known allergy to the adhesive dressing.
  • patients with physical or mental impairments who would not be able to use the new technology on their own.
  • patients with very loose/saggy skin in the neck area which would unavoidably result on AcuPebble swinging if moving the neck.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
296 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 2: PSG and novel wearable device

    75 patients will wear polysomnography at the same time as the Novel wearable device

    Diagnostic Test: Novel Wearable device

  • Group 3: PSG and novel wearable device (+ CE-marked pulse oximeter)

    51 patients (plus up to 20% to account for possible dropouts) will wear polysomnography at the same time as the novel wearable device and a CE-marked pulse-oximeter.

    Diagnostic Test: Novel Wearable device

  • Group 4: Additional PSG and novel wearable device (+ CE-marked pulse oximeter)

    Additional 75 consecutive patients will wear polysomnography at the same time as the novel wearable device and a CE-marked pulse-oximeter.

  • Group 1: Test Group

    A first group of \~10-15 patients will be recruited, chosen from those who have been referred for a sleep apnea diagnosis. This group will not be used for performance validation, but rather to train all relevant staff on the different steps of the protocol and for the initial investigation of some of the secondary objectives related to usability.

  • Group 5: RLS

    70 patients presenting clinical criteria compatible with Restless legs Syndrome and who are being evaluated for a sleep study as part of their routine clinical care will be included. The patients will wear standard polysomnography while simultaneously wearing the new wearable system (a total of 4 sensors: 1 sensor on the neck, 1 pulse oximeter on finger, and 1-2 sensors on the legs).

Interventions

  • Diagnostic testNovel Wearable device

    patient will wear novel wearable device overnight along with normal standard of care

06

What researchers measure

Primary outcomes

  1. Sensitivities and Specificity for diagnosis of sleep apnoea studies with novel wearable device

    The study aims to compare the diagnosis result of the novel wearable device against standard of care

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Virgen Macarena Sevilla
    Seville, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Dec 2028, 111 months after the start.

Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's planned 111 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2024 → Dec 2028 and completion Dec 2024 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2019
First posted
Jul 22, 2019
StartActual
Sep 30, 2019
Primary completionEst.
Dec 31, 2028was Dec 2024
CompletionEst.
Dec 31, 2028was Dec 2024
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2024→Dec 31, 2028
Nov 18, 2026
Study completion
Dec 30, 2024→Dec 31, 2028
Nov 18, 2026
Enrollment
150→296
Nov 18, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • Removedpatients with pacemakers or who have any type of implanted electronic device
Nov 18, 2026
Interventions
Arm changed PSG and novel wearable device→Group 2: PSG and novel wearable device. Arms added: Group 3: PSG and novel wearable device (+ CE-marked pulse oximeter)·Group 4: Additional PSG and novel wearable device (+ CE-marked pulse oximeter)·Group 1: Test Group·Group 5: RLS; arms removed: PG and novel wearable device
Nov 18, 2026
Contact
Study contact changed: o•••@acurable.com · •••7020→r•••@acurable.com · •••7020. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Dec 30, 2024→Dec 31, 2028
    Study completion Dec 30, 2024→Dec 31, 2028
    Enrollment 150→296
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • Removedpatients with pacemakers or who have any type of implanted electronic device
    Interventions Arm changed PSG and novel wearable device→Group 2: PSG and novel wearable device. Arms added: Group 3: PSG and novel wearable device (+ CE-marked pulse oximeter)·Group 4: Additional PSG and novel wearable device (+ CE-marked pulse oximeter)·Group 1: Test Group·Group 5: RLS; arms removed: PG and novel wearable device
    Contact Study contact changed: o•••@acurable.com · •••7020→r•••@acurable.com · •••7020. See the current contact
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04028011
Lead sponsor
Acurable Ltd.
Collaborators
Hospital Universitario Virgen Macarena
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Sep 30, 2019
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Renard Pramono, PhD
Contact
renard@acurable.com
+447721 877020
Jesus Fernando Sanchez Gomez, MD
principal investigator · Hospital Universitario Virgen Macarena

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion